The experimental therapy, fidanacogene elaparvovec, reduced the annualized bleeding rate of total bleeds by 71 percent. The trial compared the one-time gene therapy treatment to the current treatment for the rare blood disorder, which is a prophylaxis regimen.
Pfizer said it will share the data with regulators in 2023.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
